Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
ABVC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
14.08. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
27.06. | ABVC BIOPHARMA, INC. - S-8, Securities to be offered to employees in employee benefit plans | 15 | SEC Filings | ||
04.06. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
30.04. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
15.04. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
15.04. | ABVC BIOPHARMA, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
14.11.24 | ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones | 215 | GlobeNewswire (Europe) | ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could... ► Artikel lesen | |
22.10.24 | ABVC BioPharma, Inc.: ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners | 145 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NANOREPRO | 1,775 | +3,20 % | HV-Termine: Hauptversammlungen u.a. bei Baywa, Circus, Daldrup, Laiqon, NanoRepro, Pyramid, Umweltbank | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - S-1/A, General form for registration of securities | ||
BIOXXMED | 0,120 | 0,00 % | PTA-News: bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung | DJ PTA-News: bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
OCUGEN | 1,530 | +2,17 % | Ocugen plant drei Zulassungsanträge für Gentherapien gegen Erblindung bis 2028 | ||
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
BIO-GATE | 0,900 | -3,23 % | EQS-News: Bio-Gate AG: Bio-Gate veröffentlicht Halbjahreszahlen und bestätigt den Ausblick für 2025 | EQS-News: Bio-Gate AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
Bio-Gate veröffentlicht Halbjahreszahlen und bestätigt den Ausblick für 2025
30.09.2025 / 15:07... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,467 | +0,65 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations | Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
VAXART | 0,350 | +25,00 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
REDHILL BIOPHARMA | 2,050 | -6,82 % | RedHill Biopharma stock surges after court upholds $10M judgment | ||
BURCON NUTRASCIENCE | 1,410 | +4,44 % | Burcon NutraScience Corporation: Burcon Announces New Board Members and Results of Shareholder Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 5,850 | +0,52 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors | Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical... ► Artikel lesen | |
IMMUNIC | 0,817 | -0,85 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in October | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in October
01.10.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen |